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Abstract  
Objectives: Isothiocyanates (ITC) has long been shown to demonstrate chemopreventive properties. Sulforaphane 
(SFN) is a major ITC present in broccoli and other cruciferous vegetables. We reviewed the current literatures of SFN 
on ovarian carcinoma cell lines. 
Methods: Studies were conducted on the effects of SFN on the growth of the OVCAR-3, MDAH 2774 and SKOV-3 
ovarian carcinoma cell lines. Chuang et al. evaluated the effect of SFN on ovarian cancer cell cycles. Subsequently 
Chaudhuri et al. determined the specific pathway that was affected and Bryant et al. explored the signaling 
mechanisms through which SFN influences the cell growth and proliferation in ovarian cancer cell lines.  
Results: Chuang et al. showed a concentration dependent decrease in cell density. Analysis of cell cycle phase 
progression revealed a decrease in the cell populations in S and G2M phases, with an increase of G1 cell population, 
indicating a G1 cell cycle arrest. The degree of decrease in the replicating population was concentration and time 
dependent. These results clearly demonstrated an effect of SFN in inducing growth arrest and apoptosis in ovarian 
carcinoma cell lines. Chaudhuri et al. investigated the effects of sulforaphane on Akt signal transduction pathway. 
Both total Akt protein and active phosphorylated levels of Akt and phosphoinositide 3-kinase were significantly 
decreased in sulforaphane-treated ovarian cancer cell lines. Utilizing gene expression profile analysis, Bryant et al. 
showed SFN treatment resulted in G1 cell cycle arrest through down modulation of RB phosphorylation and by 
protecting the RB-E2F-1 complex. 
Conclusions: SFN induced growth arrest and cell death in ovarian cancer cells in G1 cell cycle arrest. The Akt pathway 
was identified as the possible target for SFN. SFN suppresses growth of ovarian cancer cells in vitro by modulating cell 
cycle regulatory proteins and by enhancing apoptosis. Inhibition of retinoblastoma (RB) phosphorylation and reduction 
in levels of free E2F-1 appear to play an important role in ovarian cancer growth arrest, migration, and invasion. 
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Ovarian cancer is the most common cause of death 
from gynecologic cancers in the US. In 2013, 
22,240 new cases will be diagnosed, and 14,030 
women will die of ovarian cancer[1]. Ovarian cancer 
accounts for 5% of all cancer deaths in women in 
the United States. The etiology of ovarian cancer has 
not been clearly identified. Endocrine, genetic, and 
environmental factors are implicated in ovarian 
cancer carcinogenesis. Ovarian cancer can originate 
from epithelial, germ or stromal cells in the ovaries; 
epithelial ovarian cancer (EOC) is the commonest 
histologic type and represents 90% of ovarian 
cancer [2]. EOC can be categorized into four major 
subtypes, including serous, mucinous, endometrioid, 
and clear cell carcinomas. The serosal surface of 
ovary has long been regarded as the cell of origin for 
EOCs. It has its highest incidence in industrialized 
Western and Asian countries. In previous studies, a 
diet high in animal fat has been reported to be 
associated with an increased risk of ovarian 
cancer[2]. However, other case-control studies failed 
to show that fat, protein, fiber, vitamins A and C 
elevated the risk of ovarian cancer [3] . In 
prevention of the development of ovarian cancers, 
factors that induce anovulation, including oral 
contraceptives, pregnancy, and breast feeding, are 
associated with a reduced risk of ovarian cancer [4]. 
A recent study suggested that fenretinide, a synthetic 
retinoid, might protect women from development of 
ovarian cancers. Additionally, synthetic retinoids, 
such as CD437 and AHPN, were found to inhibit the 
growth of ovarian carcinoma via retinoic acid 
receptors [5]. However, cancer cells have often 
showed resistance to retinoids. Non-steroid 
anti-inflammatory agents, such as acetylsalicylic 
acid (ASA), acetaminophen and COX-2 inhibitor 
(NS-398) were among those tested using OVCAR, 
SK-OV-3, and CAOV-3 cell lines. Recently, the 
focus has been on cancer prevention by natural 
constituents from cruciferous vegetables. The intake 
of cruciferous vegetables, such as cabbage, 
cauliflowers, broccoli, kale and brussels sprouts, has 
been shown to reduce the risk of lung, pancreas, 
prostate, colon, thyroid, bladder, skin and stomach 
cancers in rodent models[6]. Isothiocyanates (ITC) 
has long been shown to demonstrate 
chemopreventive properties. Sulforaphane (SFN) is 
a major ITC present in broccoli and other 
cruciferous vegetables. We conducted a review on 
the current literatures studying the effect of 
Sulforaphane (SFN) on ovarian cancer cell lines. 
The cell lines that were studied included OVCAR 
(high resistant to cisplatin), SK-OV-3 (Akt 
over-expressing estrogen ovarian cancer cell line), 
and CAOV-3 cell lines (ovarian mucinous 
adenocarcinoma cancer cell line) [7]. Other cell 
lines tested in studies included A2780 (cisplatin 
resistant cell line), MDAH 2774 (ovarian 
endometrioid adenocarcinoma cell line), C3, and T3 
(mouse ovarian cancer cell line) cell lines. 
Sulforaphane induces growth arrest and 
apoptosis in human ovarian cancer cells 
The protective effects of these cruciferous 
vegetables against cancer are thought to be at least 
partially due to their high content of 
glucosinolates[8]. Isothiocyanates (ITCs) are among 
the hydrolysis products of the glucosinolates. 
Myrosinase, an enzyme found in plants, in a 
separate compartment from glucosinolates, catalyses 
the hydrolysis of glucosinolates. When the plant 
cells are cut or chewed, myrosinase comes in 
contact with the glucosinolates, and hydrolysis takes 
place.  
Sulforaphane (1-isothiocyanate-4-methyl-sulfonyl 
butane) (SFN) is an ITC that broccoli is rich in. The 
chemopreventive properties of SFN are thought to 
involve the inhibition of phase 1 enzymes, such as 
P450s, and the induction of phase 2 detoxifying 
enzymes, hence, facilitating carcinogen removal[9]. 
An increasing body of evidence has indicated that 
these dietary factors are not only chemopreventive, 
but also capable of regulating the growth of 
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malignant cells, and thereby inhibiting the 
progression of carcinogenesis[10]. Chiao et al. were 
the first to report that SFN is a strong mediator of 
growth arrest and apoptosis in prostate cancer cells 
[8]. SFN has since been demonstrated to induce 
apoptosis and growth arrest in other cancer cells [10, 
11]. Tang and Zhang demonstrated that ITCs induce 
apoptosis by damaging the mitochondrial membrane 
in the transformed cell, resulting in the release of 
cytochrome C and caspase-9 activation [11]. In 
addition, modulation of the bcl-2 family proteins 
also contributes to mitochondrial membranes 
damage. To determine if SFN and its major 
metabolite is effective against ovarian cancer cells, 
the effects of SFN in ovarian cancer cell lines, 
OVCAR-3 and SKOV-3 were studied[12]. 
Sulforaphane (SFN) was cultured with OVCAR-3 
and SKOV-3 cell lines at a concentration of 1×106 
cells/ml. Apoptotic cells were determined by their 
characteristic morphology, and by the presence of 
DNA strand breaks with terminal deoxynucleotidyl 
transferase-mediated biotinylated UTP nick-end 
labelling (TUNEL). Analysis of cell cycle phases 
was performed using a Becton-Dickinson FACScan 
flow cytometer. 
Chuang et al. found a significant reduction in the 
OVCAR-3 and SKOV-3 cell density after exposure 
to SFN for 2 days. Figure 1 shows that in contrast to 
the control culture without SFN, which increased 
from 1×106 to 1.8×106 ml, the OVCAR-3 cells 
exposed to 2 µMOL/L SFN decreased to 
0.82×106±0.01, approximately 50% of the control. 
Similarly, the number of cells in cultures treated 
with 10 and 50 µmol/l SFN showed 58±2 and 
66±1.1% decrease in cell densities compared to 
control cultures (p<0.0001). 
  
 
 
 
 
 
 
Figure 1 In contrast to the control culture without SFN, which increased from 1×106 to 1.8×106 ml, the OVCAR-3 
cells exposed to 2 µMOL/L SFN decreased to 0.82×106±0.01, approximately 50% of the control. Similarly, the 
number of cells in cultures treated with 10 and 50 µMOL/L SFN showed 58±2 and 66±1.1% decrease in cell densities 
compared to control cultures (p<0.0001). 
The inhibition of proliferation of SFN on ovarian 
cancer cell lines analyzed showed 60% reduction in 
cells in the S-phase. Concomitantly, an 
accumulation of cells in G1-phase was observed, 
indicating that the transition from G1- to S-phase 
was inhibited. The TUNEL method was used to 
determine the presence of apoptosis. The presence 
of apoptotic cells could be detected within 4 h of 
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SFN exposure. Figure 2(A) demonstrates that the 
effect of SFN is concentration dependent. Two-day 
exposure of OVCAR-3 cells to 2, 10 and 50 µmol/l 
SFN in suspension cultures showed that 6.5±0.5, 
8.7±0.9 and 17.4±1.8%, respectively, of the cells 
were apoptotic (p<0.0001). When the OVCAR-3 
cells were incubated with 10 µmol/l SFN for various 
time periods, the percentage of apoptotic cells 
increased with incubation time. In this regard, 
Figure 2(B) shows that after 2- and 3-day exposure 
to 10 µmol/l SFN, approximately 18.7±2 and 
42.5±5% of the cell population were apoptotic, 
respectively (p<0.0001). These results indicate that 
an increased quantity of apoptotic cells was detected 
after a longer culture period with SFN at lower 
dosages.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (A) The effect of SFN is concentration dependent. Two-day exposure of OVCAR-3 cells to 2, 10 and 50 
µMOL/L SFN in suspension cultures showed that 6.5±0.5, 8.7±0.9 and 17.4±1.8%, respectively, of the cells were 
apoptotic (p<0.0001). (B) After 2- and 3-day exposure to 10 µMOL/L SFN, approximately 18.7±2 and 42.5±5% of the 
cell population were apoptotic, respectively (p<0.0001).  
The results of this study demonstrated that SFN 
inhibited two different ovarian cancer cell lines, 
OVCAR-3 and Akt-overexpressing SKOV-3 cell 
lines. There was a concentration dependent decrease 
in ovarian cancer cell density. On the analysis of cell 
cycle phase progression, the decrease was in the cell 
populations in S and G2M phases, with an increase 
of G1 cell population. This demonstrated a G1 cell 
cycle arrest. The degree of decrease in the 
replicating population correlated to the 
concentration and time of incubations with SFN. As 
much as 17% of apoptosis was observed on 
OVCAR-3 cells with 50 µmol/l of SFN. In addition, 
when OVCAR-3 cells were exposed to SFN for 
various time periods, the percentage of cells 
undergoing apoptosis was directly proportional to 
the incubation period. In this regard, while 18% of 
the cells underwent apoptosis after 2 days, 42% of 
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the cells showed apoptosis after 3 days of 
incubation.  
In mammalian cells, it has been reported that a 
concentration of 20 µmol/l of SFN was measured in 
the urine samples of human ingested broccoli [13]. 
This result indicated that SFN is bio-available. It has 
been estimated that approximately 20 µmol/l SFN 
can be derived from consumption of 50 g of broccoli. 
This level exceeds the concentrations of SFN 
utilized in this study. The concentrations of SFN 
used may be utilized in vivo assays [14]. 
In this paper, Chuang et al. presented the first 
report of the effects of SFN on two different human 
ovarian cancer cell lines, OVCAR-3 and SKOV-3. 
They suggested that SFN might be one of the most 
popular chemopreventive agent derived from natural 
sources in ovarian cancers. 
Antiproliferative activity of sulforaphane in 
Akt-overexpressing ovarian cancer cells 
The etiology of epithelial ovarian cancer is thought 
to be a result of the neoplastic transformation of the 
ovarian epithelium or the ampullary portion of the 
fallopian tubes. Overexpression of proto-oncogenes 
and signaling pathways such as ras are mutated, and 
Akt, epidermal growth factor receptor, 
platelet-derived growth factor/vascular endothelial 
growth factor receptor, and vascular endothelial 
growth factor are seen in ovarian cancer [15]. Signal 
transduction pathways are major target for treatment 
in ovarian cancer, and the serine-threonine kinase 
Akt has generated great interest. Akt has 
wide-ranging receptors and is activated by 
phosphatidylinositol-3,4,5,-triphosphates, which are 
generated by phosphoinositide 3-kinase (PI3K) and 
mediates downstream events regulated by PI3K 
[16-20]. Akt phosphorylates many different 
molecules that are important in the cell cycle, 
glycogen synthesis, cell death, and survival. 
Components of the PI3K/Akt pathway are 
frequently overexpressed in ovarian cancer and are 
thought to play major roles in ovarian cancer 
carcinogenesis [21]. The overexpression of the Akt 
pathway is frequently associated with poor 
prognosis and more aggressive phenotype in patients 
with ovarian cancers [22]. Consequently, agents that 
target on Akt pathway and the downstream 
molecules may mitigate the adverse oncogenic 
effects of Akt.  
Chaudhuri et al. examined the effects of 
sulforaphane on SKOV3, a human ovarian cancer 
cell line that is highly resistant to cytotoxic agents, 
such as cisplatin, adriamycin, and the tumor necrosis 
factor [23]. The effects of sulforaphane on mouse 
ovarian cancer cell lines C3 and T3, which were 
engineered to constitutively overexpress activated 
Akt were studied. Antiproliferative effects of SFN 
were studied as a function of time and dose. After 
treating the cell lines with 1, 5, 10, 20, and 40 
μmol/L of SFN, 0.025% Coomassie brilliant blue 
R250 (in 50% methanol and 10% acetic acid) was 
used for the clonogenic assay. The steady-state 
levels of cellular proteins were evaluated by Western 
Bolt Analysis using the antibodies including cuclin 
D1, cyclin-dependent kinase 4 (cdk4), cdk6, Akt, 
pAkt, PI3K p85 subunit, and actin. The Akt kinase 
assay was done using the nonradioactive Akt kinase 
assay kit in SKOV3 and C3 cell extracts ± SFN. 
ELISA kit was used to detect the apotosis induced 
by SFN on the cell lines. Finally the changes in cell 
morphology were evaluated using the inverted Zeiss 
Axiovert 200 microscope using Axiovision 4.3 
software. Chaudhuri showed sulforaphane 
down-regulates PI3K, Akt, and phosphorylated Akt 
(pAkt). The consequent loss in the kinase activity 
leads to potent antiproliferative effects and induction 
of apoptosis in ovarian cancer cell lines.  
In this study, antiproliferative effects of 
sulforaphane were tested on SKOV3, C3, and T3 
cell lines by the XTT assay. Cell survival decreased 
with increasing doses of sulforaphane, and near total 
loss of cell viability was observed at 100 μmol/L 
sulforaphane (Figure 3). The IC50 was determined 
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to be 40 μmol/L for SKOV3 cells and 25 μmol/L for 
C3 and T3 cell. The results show sulforaphane as a 
potent antiproliferative agent against ovarian cancer 
cells. As Akt is constitutively expressed in SKOV3, 
C3, and T3 cell lines, the treatment of SKOV3, C3, 
and T3 cells with sulforaphane resulted in 
down-regulation in the steady-state levels of total 
Akt protein as well as the active pAkt (Ser473) at 24 
h (Figure 4). A dose-dependent down-regulation of 
PI3K was also observed in all three cell lines upon 
treatment with sulforaphane at 24 h. A decrease in 
total Akt protein levels was observed at 40 μmol/L 
sulforaphane, with no significant changes observed 
in PI3K levels in C3 and T3 cell lines. In the case of 
SKOV3 cells, 12-h treatment of sulforaphane led to 
a decrease in pAkt levels, but no effects were 
observed on total Akt and PI3K levels. The 
manifestation of this activity occurs between 12 and 
24 h of sulforaphane treatment, with significant 
changes in protein levels only at 24 h. The results 
show that sulforaphane inhibits the PI3K/Akt 
pathway by down-regulating the key enzymes in this 
pathway, indicating the Akt pathway as a possible 
target of sulforaphane. A significant reduction in the 
kinase activity of Akt was observed in SKOV3 and 
C3 cells treated for 24 h with 10, 20, and 40 μmol/L 
sulforaphane. Their results show that sulforaphane 
inhibits the kinase activity of Akt and may account 
for the antiproliferative effects of sulforaphane in 
ovarian cancer. Sulforaphane affects critical proteins 
involved in the G1-S transition of the cell cycle. 
SKOV3, C3, and T3 cells were treated with 10, 20, 
and 40 μmol/L sulforaphane for 12 and 24 h, and the 
whole-cell lysates were used to detect the 
steady-state levels of cyclin D1, cdk4, and cdk6. A 
down-regulation of cyclin D1, cdk4, and cdk6 levels 
was detected with increasing concentration of 
sulforaphane for 24 h in all three cell lines, leading 
to a possible cell cycle arrest and decrease in 
proliferation (Figure 5). This corroborates the 
antiproliferative effects of sulforaphane on three cell 
lines, which is manifested by the induction of 
programmed cell death (Figure 6).  
 
Figure 3 Dose- and time-dependent antiproliferative effect of sulforaphane (SFN) on SKOV3 (A), C3 (B), and T3 (C) 
cells by the XTT assay. Cells were treated with varying concentrations (10, 20, 40, 60, 80, and 100 μmol/L) of 
sulforaphane were added to each well for 24 h (▲) and 48 h (○). Percentage cell survival was determined by XTT 
assay and plotted as a function of time and dose of sulforaphane.  
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Figure 4 Effect of sulforaphane on the PI3K/Akt pathway. SKOV3 (A), and C3 (B) cells were either untreated or 
treated with 10, 20, and 40 μmol/L sulforaphane for 12 and 24 h, and the steady-state protein levels of Akt, pAkt 
(Ser473), and PI3K were determined by Western blot analysis. β-Actin was used as loading control. Representative of 
three independent experiments 
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Figure 5 Effect of sulforaphane on steady-state levels of cell cycle proteins. SKOV3 (A), and C3 (B) cells were either 
untreated or treated with 10, 20, and 40 μmol/L sulforaphane for 12 and 24 h, and the whole-cell lysates were used for 
Western blot analysis of G1-S cell cycle transition markers, cyclin D1, cdk4, and cdk6. β-Actin was used as loading 
control. Representative of three independent experiments 
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Figure 6 Induction of apoptosis by sulforaphane in SKOV3 (A), and C3 (B) cells. Cell death ELISA was done and 
expressed as enrichment factor compared with untreated control (top). Columns, mean in treated cells (n = 3) of three 
experiments; bars, SD. Induction of apoptosis was also measured by cleavage of poly(ADP)ribose polymerase (PARP) 
using a specific antibody (bottom). 
Based on this study, the authors demonstrated that 
sulforaphane targets and inhibits the Akt pathway 
with a subsequent decreased functional kinase 
activity of Akt, thereby demonstrating its anticancer 
effects. The pAkt levels are down-regulated at 12 
hours in all the cells studied with minimal changes 
in total Akt and no changes in PI3K with 12 hours of 
sulforaphane treatment. A more pronounced 
down-regulation in pAkt, total Akt, and PI3K is 
observed only at 24 hours of treatment. This 
indicates that there is an early effect of sulforaphane 
on the phosphorylated form of Akt with a more 
pronounced suppressive effect at a later point on the 
pathway. These results are significant as Akt is 
constitutively expressed and active in SKOV3 
ovarian cancer cells, and C3 and T3 overexpressed 
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Akt because they were generated by the 
overactivation of the Akt oncogene. The significant 
finding is that the Akt pathway was identified as a 
target of sulforaphane in ovarian cancer. The 
PI3K/Akt pathway is considered for chemotherapy 
resistance in ovarian cancer. Mutations in the 
regulatory subunit of PI3K and the tumor-suppressor 
gene PTEN, a phosphoprotein/phospholipid 
phosphatase and negative regulator of Akt, have 
been observed in various cancers, including ovarian 
cancer. However, this study showed a 
down-regulation in the Akt levels along with a 
decrease in the functional kinase activity, thus 
identified Akt as an ideal target of sulforaphane.  
Sulforaphane induces cell cycle arrest by 
protecting RB-E2F-1 complex in epithelial 
ovarian cancer cells 
As SFN inhibits epithelial ovarian cancer cell (EOC) 
line SkOV-3 by down-regulating AKT activity [23]. 
Similar compounds such as synthetic isothiocyanate 
derivative ethyl 4-isothiocyanatobutanoate (E-4IB) 
and phenylisothiocyanates have been shown to 
induce cell death in A2780 and OVCAR-3 EOC cell 
lines [24]. Indole-3-ethyl isothiocyanate (NB7 M) 
has also shown cytotoxic activity in SkOV-3 by the 
inhibition of PIK3/AKT pathway [25]. The 
inhibition of PIK-3 and AKT pathways was reported 
in the earlier studies by the upstream events at the 
cell surface, various downstream signaling pathways 
responsible for SFN activity are not well studied. It 
is known retinoblastoma protein (RB) regulates 
G1-S phase cell cycle transition [26]. Negative 
regulation of the cell cycle is secondary to the 
ability of active, under phosphorylated RB to bind 
the transcription factor E2F-1 and repress 
transcription required for S phase progression [27]. 
In the study by Bryant et al., the authors conducted 
cell proliferation assays using two human ovarian 
cancer cell lines, MDAH-2774 and SkOV-3. Cells 
were grown as sub-confluent monolayer cultures 
and propagated under standard conditions. Cell lines 
were treated with serial dilutions of SFN dissolved 
in DMSO. Human fibroblasts were similarly treated 
to display differential cytotoxicity (data not shown). 
SFN treatment resulted in a concentration-dependent 
inhibition of the proliferation of MDAH 2774 with 
an IC50 of ~8 μmol/L (Figure 7). The extent of 
growth inhibition increased with longer interval of 
treatments and higher concentrations ranging from 5 
to 20 μmol/L. The extent of cell death with SFN 
increased as a function of dosage in 48 h as 
observed by phase contract microscopy in 
MDAH-2774 cell line. Current chemotherapy 
treatment of ovarian cancer includes paclitaxel with 
platinum based regimens, the authors evaluated the 
impact of the combination of SFN and paclitaxel in 
treating MDAH-2774 cell line. Cells treated with 
paclitaxel with or without SFN and viability was 
assessed for 72 hours. As shown in their study, 8 
μmol/L SFN which is IC50 for MDAH-2774 or 2 
μmol/L paclitaxel resulted in ~40% and ~55% cell 
death, respectively; the combination treatment 
resulted in increased cell death of ~70%.  
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Figure 7 Cells were cultured for indicated time intervals with various concentrations of the SFN. Cell growth was 
assessed by CCK-8 cell proliferation assay method. A and B are MDAH-2774 and SkOV-3 cell lines respectively. 
Graph is expressed as a percentage of control (DMSO treated cells) and represents the mean of triplicate cultures. C. 
Phase contrast pictures taken at 100× magnification after indicated concentrations of drug treatment of MDAH-2774 
cells. D. Paclitaxel mediated cytotoxicity with or without SFN on MDAH-2774 cells.  
Inhibition of cell cycle progression in tumor cells 
may be associated with a concomitant activation of 
apoptosis. Cell deaths subsequently induces changes 
on the cell surface, which results in translocation of 
phosphatidylserine (PS) from the inner layer of the 
plasma membrane to the outer layer [28]. Annexin V 
is a Ca2+ -dependent protein with high affinity for 
PS that can be used to assess apoptotic cells. The 
quantification of apoptotic changes was evaluated 
by flow-cytometry analysis after treatment with SFN. 
Control and treated cells were prepared for bivariate 
analysis using annexin V stain that detects cells 
undergoing apoptosis and propidium iodide (PI) to 
detect nonviable cells. The number of pro-apoptotic 
cells after 48 h of 10 μmol/L SFN treatment was 
significantly higher as compared with control. It was 
noted that the ratio of apoptotic cells increased with 
the increased dose of SFN treatment: approximately 
8% (5 μmol/L treatment) and 20% (10 μmol/L 
treatment) of the cells over 48-hour period. Further 
analysis was carried out by immunofluorescence 
staining with Annexin V for apoptosis after SFN 
treatment. After 48 hr exposure to 10 μmol/L SFN, 
60% of the cells stained positive for annexin V, 
whereas untreated were less than 5% annexin V 
positive.  
The causes of the growth inhibition by SFN were 
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determined by cell proliferation assays. Serum 
starved MDAH-2774 cells were treated with either 
control or 10 μmol/L SFN for 12 or 24 hrs. The cells 
were then washed, fixed, and cell cycle phase 
determination was performed utilizing flow 
cytometry and a cell cycle phase determination kit. 
SFN was found to induce G1 arrest in a 
time-dependent manner as noted in the two previous 
studies [12, 23]. There is a non-significant increase 
of S phase cells after 12 hrs (0.7%) and 24 hrs 
(2.7%) with SFN treatment compared with 40% of 
cells in S phase for control cells at 24 hrs. There was 
a substantial increase in the cells at G1 phase of the 
cell cycle after treatment with SFN. 
The genes that influence the cell cycle 
progression into S phase were studied. Tumor 
suppressor retinoblastoma proteins (RB, p107 and 
p130) sequesters cell cycle promoting E2F-1 
transcription factors [29]. Gene expression analysis 
of RB proteins revealed a 1.5 and 2.0 fold decrease 
of RB and p130, respectively; as well as, a 2 folds 
increase in p107 levels. The E2F family of proteins, 
E2F-1, 2 and 3 which interact with RB, 
demonstrated 1.0 and 1.5 fold decrease in the 
expression levels of E2F-1 and 2, respectively, and 
1.0 x increase in the levels of E2F-3. Cyclins and 
cyclin dependent kinases (CDKs) and their 
inhibitors exhibit distinct expression patterns, which 
contribute to the temporal coordination of each 
event in cell cycle progression. SFN treatment 
resulted in the lower expression of G1 phase cyclins 
and CDKs while increasing the expression of cyclin 
dependent kinase inhibitors (CKIs), which bind and 
inhibit the activity of cyclin/Cdk complexes and 
negatively regulate cell cycle progression. 
The progressive conversion of phosphorylated RB 
to non-phosphorylated RB after 48 hrs when 
MDAH-2774 cells were treated with 5 to 15 μmol/L 
SFN treatment was reported (Fig 8). It is known that 
E2F-1 is elevated in many tumor cell lines and is 
responsible for cycle pogression by the expression 
of S phase genes. Decrease in the E2F-1 protein 
levels was observed with SFN treatment. Cyclins 
and cyclin-dependent kinases (CDKs) regulate the 
activity of RB by phosphorylation resulting in 
control of progression through G1 phase to S phase 
[27]. Lower levels of the CDK4 and CDK6, were 
responsible for phosphorylation of RB in response 
to SFN was observed in a dose dependent manner. 
The authors also reported a dose dependent increase 
in the RB levels in E2F-1 immunoprecipitates [30]. 
 
 
 
 
 
 
 
 
Figure 8 A. Cells were seeded at 106 cells and grown serum-free medium for 24 hr for cell cycle synchronization. 
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Cells were then treated with either vehicle DMSO (i, ii and iii) or 10 µmol/l SFN (iv, v and vi) for 0 hours (i and iv), 
24 hours (ii and v) and 48 hours (iii and vi), respectively. Cells were fixed, stained and flow cytometric analysis was 
conducted using a cell cycle phase determination kit (Cayman chemical company, Ann Arbor, MI). B. Tabular 
representation of the % changes in the cell cycle phases. The results demonstrated that SFN induces G1 arrest in a 
time-dependent manner (D, E, F) in comparison with control cells (A, B, C). 
SFN has been reported to inhibit cell mobility and 
invasiveness. Cell motility following wound 
generation showed a greater cell migration in 
control cells compared with SFN treated cells. After 
20 hrs, Bryant et al. observed almost complete 
closure of the wound in control but was inhibited by 
50% and 75% by 5 µmol/l and 10 µmol/l SFN in 
cancer cell lines, respectively (Fig 9). SFN treatment 
also resulted in inhibition of cell migration in a 
modified Boyden chamber.  
Bryant et al. showed that SFN activates the 
RB-E2F-1 interaction with MDAH-2774 ovarian 
cancer cell line resulting the upstream AKT 
inhibition to the downstream blocking of cell cycle 
[30]. They also showed the inhibition of 
invasiveness of cells and subsequent migration.  
Conclusions 
SFN mediating cell growth arrest has been 
documented in colon, prostate and several other 
cancers [23, 31-33]. Little is known on its effects is 
gynecologic malignancies. Only three had reported 
on its effects on ovarian cancer cells [23, 30, 31, 34]. 
At a concentration of 20 µmol/l of SFN was 
measured in the urine samples of human ingested 
broccoli [13]. This result indicated that SFN is 
bio-available in human. It has been estimated that 
consumption of 50 g of broccoli can generate 20 
µmol/l of SFN. As this level exceeds the 
concentration of SFN utilized in in-vitro studies, the 
concentrations of SFN used in the study may be 
utilized in vivo assays. Chuang et al. presented the 
first report of the effects of SFN on two different 
human ovarian cancer cell lines, OVCAR-3 and 
SKOV-3 [31]. Consequently, this might make SFN 
as an attractive chemopreventive and 
chemotherapeutic agent derived from natural 
sources in ovarian cancers.  
Chaudhuri et al. demonstrated that SFN inhibits 
the growth of the ovarian cancer cells and the 
inhibition of the AKT pathway is one of the 
upstream molecular events [23]. They observed 
potent antiproliferative effects of sulforaphane in 
SKOV3, C3, and T3 cells. Sulforaphane was found 
to inhibit the clonogenic ability of ovarian cancer 
cells. The clonogenic ability is considered a marker 
of neoplastic propensity. This is significant as 
sulforaphane is able to target a small percentage of 
cells in a tumor that can survive and proliferate 
using autocrine factors and may be associated with 
up-regulated prosurvival pathways. Bryant et al. 
investigated downstream molecular mechanisms at 
the level of cell cycle control in the nucleus. 
Combination therapy with paclitaxel is known to 
increase overall survival [35], but contributes to the 
development of resistance phenotype resulting in 
eventual relapse of the disease. Unlike traditional 
chemotherapy drugs, natural therapeutics like SFN 
may not contribute to the development of 
chemo-resistant phenotype. Bryant’s results 
indicated a synergistic effect of cell death when SFN 
was used in combination with paclitaxel. 
Phosphorylated RB cannot interact with E2F-1, thus 
leaving large pool of free E2F-1 transcription factors 
driving the G1/S cell cycle transition. E2F-1 has 
been shown to have growth promoting activity in 
EOC and is over expressed in roughly half of the 
ovarian cancers [34]. Invasion followed by 
degradation of basal membrane is hallmark of tumor 
metastasis where proliferating tumor cells infiltrate 
into other tissues. Wound healing assays and 
Boyden chamber assays provide evidence that the 
cell motility and invasiveness are inhibited by SFN. 
These findings suggested that SFN has very good 
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potential for use in the treatment against invasion 
and metastasis of EOC. SFN induces growth arrest 
and apoptosis in EOC cells by inhibiting RB 
phosphorylation and reduction in the levels of free 
E2F-1.  
Future Directions 
A subset of ovarian cancer cell lines and tumors 
harbors genetic alterations activated Akt in the 
PI3K/Akt pathways, which is poor prognostic 
biomarker. Thus, selective, allosteric Akt inhibitors 
in patients with ovarian cancer are a prominent 
focus for clinical utility. Other subsets with RB1 
loss or RAS or RAF mutation were however often 
resistant to Akt inhibition, irrespective of pathway 
activation. It is also reported the selective Akt1 
inhibition was sufficient for maximal antitumor 
effects in a subset of ovarian cancer cell lines 
wheras pan-Akt inhibition was required in those 
expressing Akt3. Current literatures reported 
antitumor effects on ovarian cancer cell lines 
(SKOV3 and OVCAR3) overexpressing Akt, and 
retain RB and PTEN. In order to reach the definitive 
conclusion of SFN effect in Akt or RB, further 
analysis is needed of ovarian cancer cell lines 
without Akt activation, with RB loss or Kras 
activation. It is also needed to evaluate other subsets 
of ovarian cancer cell lines with RAS or RAF 
mutations, which is resistant to Akt inhibitors, such 
as SKOV8 cell line. Mutant p53 depletion has been 
reported as an important target for cancer 
chemoprevention and therapy by natural and 
synthetic ITCs and a critical mechanism induce 
apoptosis in various types of cancers. In such 
circumstances, SFN did not show repression of 
mutant p53 expression unless it is at a high 
concentration [36]. Addition studies are needed to 
evaluate in p53 expressing ovarian cancer cell lines. 
As refractory and recurrent ovarian cancers are often 
refractory to cisplatin and paclitaxel treatments, 
further study is required to evaluate combination of 
SFN and other agents to overcome resistance to 
treatments of these chemotherapeutic agents. 
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